Madhu Kumar
Stock Analyst at Goldman Sachs
(3.59)
# 878
Out of 4,735 analysts
153
Total ratings
55.45%
Success rate
18.96%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $169 | $121.43 | +39.17% | 7 | Jun 5, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $4.00 | +50.00% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $24.86 | +4.59% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $13.95 | +21.86% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.73 | +131.21% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $151.55 | +2.28% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $45.82 | +15.67% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $4.87 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $19.76 | +269.43% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $30.13 | +367.97% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $13.67 | +148.72% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $5.88 | +2.04% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $16.41 | -14.69% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $12.68 | +65.62% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $27.39 | -81.75% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $1.21 | +561.16% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $18.57 | +379.27% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $6 | $0.62 | +872.45% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.66 | +1,426.25% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $9.94 | +755.13% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $1.51 | +2,482.78% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $14.91 | +282.29% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.21 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $4.05 | +22,122.22% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $10.42 | +91.94% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $1.29 | +7,651.94% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $44.88 | -22.01% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $2.46 | +2,339.02% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $7.63 | +424.25% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $14.30 | +3,424.48% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $264.99 | -13.20% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $60 | $1.26 | +4,661.90% | 5 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $2.47 | +1,519.43% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $29.86 | -28.00% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $41.51 | -43.39% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Jun 5, 2024
Initiates: Buy
Price Target: $169
Current: $121.43
Upside: +39.17%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $4.00
Upside: +50.00%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $24.86
Upside: +4.59%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $13.95
Upside: +21.86%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.73
Upside: +131.21%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $151.55
Upside: +2.28%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $45.82
Upside: +15.67%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $4.87
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $19.76
Upside: +269.43%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $30.13
Upside: +367.97%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $13.67
Upside: +148.72%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $5.88
Upside: +2.04%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $16.41
Upside: -14.69%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $12.68
Upside: +65.62%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $27.39
Upside: -81.75%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $1.21
Upside: +561.16%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $18.57
Upside: +379.27%
Jan 19, 2022
Downgrades: Neutral
Price Target: $29 → $6
Current: $0.62
Upside: +872.45%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.66
Upside: +1,426.25%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $9.94
Upside: +755.13%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $1.51
Upside: +2,482.78%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $14.91
Upside: +282.29%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.21
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $4.05
Upside: +22,122.22%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $10.42
Upside: +91.94%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $1.29
Upside: +7,651.94%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $44.88
Upside: -22.01%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $2.46
Upside: +2,339.02%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $7.63
Upside: +424.25%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $14.30
Upside: +3,424.48%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $264.99
Upside: -13.20%
Jul 6, 2018
Maintains: Neutral
Price Target: $120 → $60
Current: $1.26
Upside: +4,661.90%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $2.47
Upside: +1,519.43%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $29.86
Upside: -28.00%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $41.51
Upside: -43.39%